Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians

BJU International

Volumn 108, Issue 8, 2011, Pages 1269-1273

  Yafi, Faysal A ^a   Aprikian, Armen G ^a   Tanguay, Simon ^a   Kassouf, Wassim ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

5 reductase inhibitors; benign prostatic hyperplasia; general practice; prostate cancer chemoprevention; survey

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AWARENESS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CHILD; CONSULTATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MALE; MONOTHERAPY; PATIENT REFERRAL; PHYSICIAN ATTITUDE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; RISK REDUCTION; UROLOGY;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; GENERAL PRACTITIONERS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; PRIMARY HEALTH CARE; PROSTATIC HYPERPLASIA; QUEBEC; REFERRAL AND CONSULTATION;

EID: 80053421259     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09984.x     Document Type: Review

References (27)

1. Isaacs JT, Coffey DS,. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989; 2: 33-50 (Pubitemid 20075619)
2. Burnett AL, Wein AJ,. Benign prostatic hyperplasia in primary care: what you need to know. J Urol 2006; 175: S19-24 (Pubitemid 43177188)
3. Emberton M, Andriole GL, de la Rosette J, et al,. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267-73 (Pubitemid 36206514)
4. Berry SJ, Coffee DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9 (Pubitemid 14026148)
5. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61 (Pubitemid 40380548)
6. Roehrborn CG, McConnell JD,. Etiology, pathophysiology, epidemiology and natural history of BPH. In, Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds, Campbell's Urology. Philadelphia, PA: WB Saunders Inc., 2002: Chap 86
7. Thompson IM, Goodman PJ, Tangen CM, et al,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24 (Pubitemid 36859473)
8. Andriole GL, Botswick DG, Brawley OW, et al,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
9. Fukagai T, Maruyama K, Nagata M, Morita M, Naoe M, Yoshida H,. Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners. Int J Urol 2007; 14: 412-5 (Pubitemid 46776215)
10. Kim HL, Benson DA, Stern D, Gerber GS,. Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey. Urology 2002; 59: 266-71 (Pubitemid 34134529)
11. Cornu JN, Cussenot O, Haab F, Lukacs B,. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58: 450-6
12. van Exel NJ, Koopmanschap MA, McDonnell J, et al,. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 2006; 49: 92-102 (Pubitemid 41789962)
13. McConnell JD, Roehrborn CG, Bautista OM, et al,. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
14. Roehrborn CG, Boyle P, Bergner D, et al,. Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54: 662-9 (Pubitemid 29449427)
15. Boyle P, Gould AL, Roehrborn CG,. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405 (Pubitemid 26317480)
16. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G,. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41 (Pubitemid 35292169)
17. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
18. de la Rosette JJ, Alivizatos G, Madersbacher S, et al,. European Association of Urology. EUA guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 256-64 (Pubitemid 34701895)
19. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, Trip OB,. Alpha-blockade therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6 (Pubitemid 37185673)
20. Nickel JC,. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004; 6 (Suppl. 9): S31-9
21. Oesterling JE, Roy J, Agha A, et al,. Biologic variability of prostate-specific antigen and its usefulness as a marker of prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 1997; 50: 13-8 (Pubitemid 27300358)
22. Andriole GL, Guess HA, Epstein JL, et al,. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52: 195-202 (Pubitemid 28357819)
23. Kramer BS, Hagerty KL, Justman S, et al,. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Guideline Practice. J Urol 2009; 181: 1642-57
24. Kulkami G, Al-Azab R, Fleshner N, et al,. Evidence for a volume derived grade artifact in prostate cancer. J Urol 2005; 173: S31
25. Lucia S, Darke A, Goodman P, et al,. Pathological assessment of high grade tumours in the prostate cancer prevention trial (PCPT). J Urol 2005; 173: S451
26. Andriole G, Bostwick D, Civantos F, et al,. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2005; 174: 2098-104 (Pubitemid 41611745)
27. Andriole G, Crawford ED, Grubb RL 3rd, et al,. PLCO Project Team. Mortality results from a randomized prostate-screening clinical trial. N Engl J Med 2009; 360: 1310-9